Tetrabenazine Interactions

Brand names: Tetrabenazine

Vesicular Monoamine Transporter 2 Inhibitor · Vesicular Monoamine Transporter 2 Inhibitors

FDA Black Box Warning

WARNING: DEPRESSION AND SUICIDALITY Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of tetrabenazine must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. Tetrabenazine is contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression [see Contraindications ( 4 ) , Warnings and Precautions ( 5.1 ) ] . WARNING: DEPRESSION AND SUICIDALITY See full prescribing information for complete boxed warning . Increases the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease ( 5. 1 ) Balance risks of depression and suicidality with the clinical need for control of chorea when considering the use of tetrabenazine ( 5.2 ) Monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior ( 5. 1 ) Inform patients, caregivers and families of the risk of depression and suicidality and instruct to report behaviors of concern promptly to the treating physician ( 5. 1 ) Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation ( 5. 1 ) Tetrabenazine is contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression ( 4 , 5.1 )

2 interactions on record

Tetrabenazine + MoxifloxacinMinor

7.5 Drugs That Cause QTc Prolongation Tetrabenazine tablets causes a small prolongation of QTc (about 8 msec), concomitant use with other drugs that are known to cause QTc prolongation should be avoided, these including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval.

Source: FDA drug label - tetrabenazine

Tetrabenazine + ProcainamideMinor

7.5 Drugs That Cause QTc Prolongation Tetrabenazine tablets causes a small prolongation of QTc (about 8 msec), concomitant use with other drugs that are known to cause QTc prolongation should be avoided, these including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval.

Source: FDA drug label - tetrabenazine